Put Options

18 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.42 - $0.65 $3,738 - $5,785
-8,900 Reduced 14.1%
54,200 $33,000
Q1 2022

May 16, 2022

SELL
$0.54 - $2.74 $33,480 - $169,880
-62,000 Reduced 49.56%
63,100 $38,000
Q4 2021

Feb 14, 2022

BUY
$2.33 - $3.37 $254,203 - $367,667
109,100 Added 681.88%
125,100 $334,000
Q3 2021

Nov 15, 2021

BUY
$2.52 - $2.99 $2,268 - $2,691
900 Added 5.96%
16,000 $44,000
Q2 2021

Aug 11, 2021

SELL
$2.6 - $3.65 $1,820 - $2,555
-700 Reduced 4.43%
15,100 $43,000
Q1 2021

May 17, 2021

SELL
$2.73 - $4.5 $194,376 - $320,400
-71,200 Reduced 81.84%
15,800 $54,000
Q4 2020

Feb 16, 2021

BUY
$2.6 - $3.32 $39,260 - $50,132
15,100 Added 21.0%
87,000 $230,000
Q3 2020

Nov 16, 2020

BUY
$2.46 - $4.27 $37,146 - $64,476
15,100 Added 26.58%
71,900 $224,000
Q2 2020

Aug 14, 2020

BUY
$1.45 - $4.3 $66,410 - $196,940
45,800 Added 416.36%
56,800 $235,000
Q1 2020

May 15, 2020

SELL
$0.75 - $2.55 $451,575 - $1.54 Million
-602,100 Reduced 98.21%
11,000 $18,000
Q3 2019

Nov 14, 2019

SELL
$1.48 - $2.52 $87,320 - $148,680
-59,000 Reduced 8.78%
613,100 $1.03 Million
Q2 2019

Aug 14, 2019

BUY
$2.45 - $3.32 $1.45 Million - $1.96 Million
589,800 Added 716.65%
672,100 $1.68 Million
Q1 2019

May 15, 2019

BUY
$2.52 - $3.24 $164,808 - $211,896
65,400 Added 386.98%
82,300 $253,000
Q4 2018

Feb 14, 2019

BUY
$1.92 - $4.1 $7,680 - $16,400
4,000 Added 31.01%
16,900 $45,000
Q3 2018

Nov 14, 2018

BUY
$3.39 - $4.61 $9,153 - $12,447
2,700 Added 26.47%
12,900 $56,000
Q2 2018

Aug 14, 2018

SELL
$1.89 - $4.95 $18,522 - $48,510
-9,800 Reduced 49.0%
10,200 $40,000
Q4 2017

Feb 14, 2018

BUY
$1.91 - $2.83 $3,629 - $5,377
1,900 Added 10.5%
20,000 $42,000
Q3 2017

Nov 14, 2017

BUY
$2.44 - $2.91 $44,164 - $52,671
18,100
18,100 $49,000

Others Institutions Holding MEIP

# of Institutions
1
Shares Held
2K
Call Options Held
0
Put Options Held
0

About MEI Pharma, Inc.


  • Ticker MEIP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 133,261,000
  • Market Cap $372M
  • Description
  • MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...
More about MEIP
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.